Herbal Formula Science (대한한의학방제학회지)

The Korean Medicine Society for the Herbal Formula Study (대한한의학방제학회)
권호 표지

The Anti-tumor Effect of Bojungikkeehapdaechilkitang with Doxorubicin in 3LL

보중익기합대칠기탕(補中益氣合大七氣湯)과 Doxorubicin의 병용이 3LL의 항암효과에 미치는 영향

  • Lee Yun-Hee (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Kim Bong-Suk (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Oh Jung-Han (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Lim Hee-Yong (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Kim Dong-Woo (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Choi Bin-Hye (Department of Internal Medicine, College of Oriental Medicine, Daegu Haany University) ;
  • Kim Sang-Chan (Department of Formulae Pharmacology, College of Oriental Medicine, Daegu Haany University) ;
  • Byun Joon-Seok (IDepartment of nternal Medicine, College of Oriental Medicine, Daegu Haany University)
  • 이윤희 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 김봉석 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 오중한 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 임희용 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 김동우 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 최빈혜 (대구한의대학교 한의과대학 비계내과학교실) ;
  • 김상찬 (대구한의대학교 한의과대학 방제학교실) ;
  • 변준석 (대구한의대학교 한의과대학 비계내과학교실)
  • Published : 2004.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

In order to evaluate the anti-tumor and synergic effect of Bojungikkeehapdaechilkitang with doxorubicin, the inhibitory concentration(IC), $IC_{50}\;and\;IC_{90}$ of single use of doxorubicin and Bojungikkeehapdaechilkitang with their concomitant treatment against 3LL(Lewis lung carcinoma) was observed using MTT(Microculture Tetrazolium test) assay. In addition, their anti-tumor effects were also observed in the xenograft nude mice models agianst to 3LL cell lines. Bojungikkeehapdaechilkitang has only mimic direct anti-tumor effect against to 3LL cell lines but they were decreased general depressed signs induced by implantation of tumor cell lines and increased the total WBC and lymphocyte numbers. So, it is considered or expected that Bojungikkeehapdaechilkitang extracts were reduced the critical toxicity of doxorubicin and shows favorable synergic effect with doxorubicin and Bojungikkeehapdaechilkitang extracts.

Keywords

References

  1. 東醫腫瘍學 v.1 崔昇勳
  2. 종양학 v.3 서울대학교 의과대학
  3. 건강검진을 통한 암의 발견과 암표지자의 암선별검사로서의 유용성 박경희
  4. 건강생활년을 이용한 우리 나라 주요 암 질환의 질병부담 측정 최용준
  5. Anticancer Drugs v.11 no.10 The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma Neale, M.H.;Lamont, A.;Hindley, A.;Kurbacher, C.M.;Cree, I.A.
  6. Expert Opin. Investig. Drugs v.9 no.7 New agents in the treatment of soft-tissue sarcomas Patel, S.R.
  7. 大韓韓方腫瘍學會誌 v.1 no.1 韓國韓醫學의 腫瘍硏究에 對한 現況 공현식;유봉하;박동원;유기원
  8. 大韓韓方內科學會誌 v.16 no.2 癌 治療에 있어서 扶正祛邪法의 運用에 關한 考察 孫彰奎;趙鍾寬
  9. 大韓韓方內科學會誌 v.16 no.2 現代 中國의 癌治療 硏究 現況 鄭鍾美;趙鍾寬
  10. 東醫寶鑑 v.4 許浚
  11. 少陰人補中益氣湯과 瓦松이 抗癌 및 免疫反應에 미치는 影響 田炳旭
  12. 大韓東醫病理學會誌 v.8 no.1 補中益氣湯 및 少陰人 補中益氣湯이 S-180에 對한 抗 腫瘍效果와 Cyclophosphamide에 依한 副作用에 미치는 影響 金秀鎭;林樂哲;金聖勳
  13. 大韓韓醫學會誌 v.14 no.2 消積白朮散의 抗癌, 免疫增强效果 및 Cisplatin의 腎臟毒性抑制에 미치는 影響에 關한 硏究 趙成基;趙鍾寬
  14. 方劑學 金相贊;金先熙;盧昇鉉;朴宣東;卞晟僖;徐富一(等)
  15. 醫學入門 v.1 李정
  16. 동의생리병리학회지 v.15 no.1 大七氣湯이 抗癌, 免疫調節作用 및 apoptosis에 미치는 影響 하지용;정병억;이선구;유병길
  17. 大韓韓方內科學會誌 v.29 no.2 大七氣湯의 抗癌效果에 關한 硏究 禹弘楨;李長勳;金榮哲
  18. 大韓方劑學會誌 v.5 no.1 腫瘍의 治法에 關한 實驗的 硏究 김선희;김상찬;최종백
  19. 國譯 萬病回春 공廷賢
  20. 濟衆新編 康命吉
  21. Blood v.91 no.2 The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors Masse, A.;Ramirez, L.H.;Bindoula, G.;Grillon, C.;Wdzieczak-Bakala, J.;Raddassi, K.;Deschamps de Paillette, E.;Mencia-Huerta, J.M.;Koscielny, S.;Potier, P.;Sainteny, F.;Carde, P.
  22. A guide to laboratory diagnosis Laboratory profiles of small animal diseases Sodikoff, C.H.
  23. 最近 癌의 豫防과 治療傾向 김삼용
  24. 大韓免疫學會誌 v.8 no.1 癌免疫學과 免疫療法 金鎭福
  25. 최신지견 내과학 v.1 서울대학교 의과대학 내과학교실
  26. Ann. Intern. Med. v.91 no.5 Risk factors for doxorubicin-induced congestive heart failure Von Hoff, D.D.;Layard, M.W.;Basa, P.;Davis, H.L. Jr.;Von Hoff, A.L.;Rozencweig, M.;Muggia, F.M.
  27. Mutat. Res. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract Bagchi, D.;Sen, C.K.;Ray, S.D.;Das, D.K.;Bagchi, M.;Preuss, H.G.;Vinson, J.A.
  28. Phytomedicine v.7 no.2 Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa Sheng, Y.;Pero, R.W.;Wagner, H.
  29. 儒門事親 v.1 張子和
  30. 廣濟秘급 v.1 李景華
  31. Anticancer Res. v.8 no.1 Antitumor effect and cardiotoxicity of a doxorubicin-lecithin association Bellelli, A.;Giomini, M.;Giuliani, A.M.;Giustini, M.;Lorenzon, I.;Rusconi, V.;Sezzi, M.L.;Trotta, E.;Belleli, L.
  32. J. Antibiot.(Tokyo) v.40 no.11 Antitumor effect of kazusamycin B on experimental tumors Yoshida, E.;Komiyama, K.;Naito, K.;Watanabe, Y.;Takamiya, K.;Okura, A.;Funaishi, K.;Kawamura, K.;Funayama, S.;Umezawa, I.
  33. Eur. J. Cancer Clin. Oncol. v.19 no.3 Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice Broggini, M.;Ghersa, P.;Donelli, M.G.
  34. J. Med. Chem. v.34 no.3 N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis lung carcinoma Schnur, R.C.;Fliri, A.F.;Kajiji, S.;Pollack, V.A.
  35. Cancer Res. v.49 no.14 Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1 Eppstein, D.A.;Kurahara, C.G.;Bruno, N.A.;Terrell, T.G.
  36. J. Toxocol. Environ. Health v.18 no.2 Reference range data base for serum chemistry and hematology values in laboratory animals Wolford, S.T.;Schroer, R.A.;Gohs, F.X.;Gallo, P.P.;Brodeck, M.;Falk, H.B.;Ruhren, R.